DIRS.INFO The most relevant business & tech news

☆ Expect AI-made prescription drugs to be ready for clinical trials in a couple of years, predicts Google DeepMind CEO
▼ + stars: | 2024-02-26 | by ( Sarah Jackson | ) www.businessinsider.com time to read: 1 min

AdvertisementOne of the foremost figures in AI thinks prescription drugs designed by AI could reach clinical testing in a few years. Google DeepMind CEO Demis Hassabis discussed his prediction on an episode of The New York Times podcast "Hard Fork" released Friday. "I think we are very close," Hassabis said when asked about whether AI was close to being capable of helping cure a major disease like Alzheimer's or a cancer. "I would say we're a couple of years away from having the first truly AI-designed drugs for a major disease, cardiovascular, cancer." This story is available exclusively to Business Insider subscribers.

Persons: Demis Hassabis, Hassabis Organizations: Google, The New York Times, Business

☆ VCs are clamoring to back 'screaming hot' startups using AI for medical records
▼ + stars: | 2024-02-21 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +7 min

Another AI medical records startup, DeepScribe, raised a $30 million Series A round in January 2022. AbridgeThe investor descent on medical-scribe startups reflects a blatant potential of automation tech to alleviate healthcare’s most critical issues. “This market is screaming hot,” said Bryan Roberts, a partner at Venrock and an investor in medical-scribe startup Suki. AdvertisementStill, as health systems increasingly adopt AI solutions to manage labor costs, these startups have room to grow into their valuations. Medical-scribe startups vying for the remaining slice of the pie are “in a pitch to the death,” Roberts said.

Persons: —, ’, Kleiner Perkins, Andreessen Horowitz, Suki, Punit Soni, Shiv Rao, ”, Bryan Roberts, ” Roberts, Annie Case, Case, Hermann, Keith Srakocic, Roberts, there’s, “ Organizations: Service, Business, Healthcare, Fund, Optum Ventures, Medical, Cathay Innovation, Microsoft, University of Pittsburgh Medical Center, University of Kansas Health, AP

☆ Healthcare startups are rushing to sell AI to hospital systems. But a new survey suggests many simply aren't ready for it.
▼ + stars: | 2024-02-20 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +4 min

As healthcare startups dive headfirst into building artificial intelligence products to sell to hospitals, a new report suggests many health systems don't yet have policies to support the tech. In a survey of 34 US health systems leaders, only 16% reported having systemwide policies for AI usage and data access. Some health system leaders said they haven't developed policies because the industry is in the early stages of AI adoption. Many health system leaders surveyed by KLAS expressed excitement about AI software for clinical documentation. Seventy percent of health system leaders surveyed by KLAS said their organizations planned to adopt AI software integrated with their EHRs.

Persons: —, hasn't, Robert Califf, KLAS, we'll, Bryan Roberts Organizations: Business, Center, Medicine, UPMC, KLAS Research, Healthcare, Food and Drug Administration, FDA, Venture, University of Pittsburgh Medical Center, University of Kansas Health, Microsoft, Industry

☆ How to fight dementia, according to neurologists
▼ + stars: | 2024-02-12 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +17 min

What about diabetes, cancer, thyroid disease, high blood pressure or heart disease? Some of the questions might seem unexpected to those who don’t write about brain health. However, my risk of developing vascular dementia, the second most common type after Alzheimer’s disease, is elevated. "Such spikes cause brain inflammation, disrupt brain metabolism and increase shrinkage of the thinking part of the brain," Isaacson said. The National Institute on Aging currently supports nearly 500 active clinical trials on Alzheimer’s disease and related dementias.

Persons: Louise Dittner, Krysta, Ryan LaMotte, It’s, ”, Natalia Rost, “, Rost, ” Rost, Richard Isaacson, ” Isaacson, mockingbird …, birthed, it’s, I’ve, Isaacson, Sandee LaMotte Organizations: CNN, Comprehensive, Massachusetts General Hospital, Harvard Medical School, American Academy of Neurology, Boca Raton, Weill Cornell Medicine, Presbyterian, Mayo Clinic, Volunteers, Alzheimer’s, National Institute on Aging, National Institutes of Health Locations: Massachusetts, Boston, neonatologists, Florida, United, New York, New York City, Nature

☆ Exclusive: Astarte Medical is shutting down. Here's why the infant tech startup decided to close its doors.
▼ + stars: | 2024-02-05 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +7 min

Tracy Warren cofounded Astarte Medical in 2016 to improve care for premature babies. Astarte, which sells software to standardize nutrition for babies in intensive care units, had raised $14 million in venture funding to date and landed contracts with four hospitals. Last year, the startup wasn't able to land as many new contracts as it hoped, with hospitals struggling to manage their slim margins. But Astarte ultimately decided not to make the promise to build AI into its tech for clinical decision-making. The startup is hoping to find a buyer by the end of the first quarter of the year.

Persons: Tracy Warren, Warren, Astarte, Tammi Jantzen, Katherine Gregory, Gregory, Warren didn't, Nenov, Jantzen, —, we've, we're, Medical's Organizations: Business, Brigham, Women's, Viking Global, Ben Franklin Technology Partners, Children's, Gillette Children's Hospital, Children's Hospital, Arkansas Children's Hospital Locations: Virginia, Minnesota, Arkansas

☆ New blood test that screens for Alzheimer’s may be a step closer to reality, study suggests
▼ + stars: | 2024-01-22 | by ( Jacqueline Howard | ) edition.cnn.com time to read: +11 min

Alzheimer’s disease, a brain disorder that affects memory and thinking skills, is the most common type of dementia, according to the National Institutes of Health. “A blood test being negative speeds up the investigation for other causes of the symptoms and this is just as important,” Ashton said. Isaacson, who has researched blood biomarkers in people with no or minimal cognitive complaints, likened testing blood samples for signs of Alzheimer’s disease to how people undergo routine blood tests for high cholesterol. It is possible that currently available treatments for Alzheimer’s disease would work better in those diagnosed early in this way,” he said. The combination of a simple screening test with an effective treatment for Alzheimer’s disease would have a dramatic impact for individuals and for society.”

Persons: ” Nicholas Ashton, Ashton, ”, Kaj Blennow, Henrik Zetterberg, antiamyloid, immunoassay, ” Ashton, Richard Isaacson, ” Isaacson, Isaacson, ‘, “, Dr, Sanjay Gupta, David Curtis, ” Curtis Organizations: CNN, University of Gothenburg, National Institutes of Health, Quest Diagnostics, Alzheimer’s, Alzheimer’s Association, Get CNN, CNN Health, University College London, Science Media Locations: Sweden, United States, Wisconsin, Pau, Florida

☆ Here's why a top VC says healthcare investors should make growth-stage bets right now — and where he's looking for those deals
▼ + stars: | 2024-01-18 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +5 min

As a multi-stage VC fund, Lightspeed has an advantage in its exposure to both early-stage and later-stage healthcare markets, Imanbayev said. And many later-stage healthcare startups still have plenty of room to grow, he said. The first one to three years are often slow-moving for a healthcare startup, too, as it works to get its first partnerships with payers or providers, he said. But they also tend to be less risky, since later-stage startups should have revenue streams or partnerships that demonstrate their value. Lightspeed led value-based care startup Aledade's $260 million Series F in June 2023, an unusually large deal as other investors cut much smaller checks.

Persons: —, Galym, Imanbayev, I'm, There's, Farzad Mostashari, Aledade Tom Sandner, VCs, Abridge, he's, Chris Severn Organizations: Business, Lightspeed Venture Partners, Lightspeed, CVS, Health, Turquoise Health, Pharma, FDA, pharma

The full benefit for these Indian manufacturers will not be immediate, said Peter DeYoung, CEO of Piramal Pharma Solutions. Nimgaonkar said Indian CDMOs need to do more to ensure their reputation on quality standards matches Western and Chinese ones. The Indian CDMOs told Reuters that their facilities are routinely inspected by the FDA. Aragen counts seven of the 10 biggest pharma companies as clients, he said, declining to name them. "New biotechs are deciding to put eggs in both the Indian and China baskets from the start," Subramanian said.

Persons: Trump, Tommy Erdei, Ashish Nimgaonkar, Nimgaonkar, Sai, Peter DeYoung, Helen Chen, CDMOs, Piramal, DeYoung, Ramesh Subramanian, Subramanian, Maggie Fick, Andrew Silver, Michele Gershberg, Catherine Evans Organizations: Jefferies, Glyscend Therapeutics, Reuters, Sciences, Piramal Pharma, Sai Life Sciences, Western pharma, Piramal Pharma Solutions, L.E.K, Consulting, pharma, U.S . Food, Drug Administration, FDA, Thomson Locations: China, India, SHANGHAI, HYDERABAD, U.S, Shanghai, United States, London, Hyderabad

☆ F.D.A. Experts Will Vote on Safety of a Cure for Sickle Cell Disease
▼ + stars: | 2023-10-30 | by ( Gina Kolata | More About Gina Kolata | ) www.nytimes.com time to read: +4 min

An estimated 100,000 people in the United States have sickle cell disease, most of whom have African ancestry. will decide on another application for sickle cell gene therapy made by Bluebird Bio. Two other companies and an academic center, Boston Children’s Hospital, are testing their own sickle cell gene therapies. While these therapies could reduce the suffering of sickle cell patients in the United States and other wealthy countries, there is an even greater need for them in some developing countries like Nigeria. One company, Beam, is testing a way to provide gene editing that requires nothing more than a single infusion in a doctor’s office.

Persons: “, Mariah Jacqueline Scott, Scott, ”, Stephan Grupp, What’s Organizations: Institute for Clinical, CRISPR Therapeutics, Children’s Hospital of Philadelphia, Bluebird, Boston Children’s Hospital Locations: United States, Highland Park, N.J, Boston, Nigeria

☆ Pfizer to price COVID treatment Paxlovid at $1,390 per course
▼ + stars: | 2023-10-18 | by ( Michael Erman | ) www.reuters.com time to read: +3 min

The new list price, which does not include rebates and other discounts to insurers and pharmacy benefit managers, is $1,390 per course, Pfizer said in an emailed statement. The U.S. government paid around $530 per course for Paxlovid it has made available to Americans at no cost. The United States purchased around 24 million courses of the oral two-drug treatment from Pfizer, and still had a large supply, but arranged to return 7.9 million courses last week. In 2022, patients were given around 7 million courses of the drug, according to U.S. government data. Through Oct. 1, around 3.4 million courses had been administered in 2023.

Persons: Wolfgang Rattay, Paxlovid, Michael Erman, Bill Berkrot Organizations: REUTERS, Pfizer, for Clinical, Economic, United, Wall Street, Thomson Locations: U.S, United States, Maplewood , N.J

☆ Why nursing schools are turning away applicants amid a major staffing shortage
▼ + stars: | 2023-10-05 | by ( Tami Luhby | ) edition.cnn.com time to read: +8 min

CNN —At a time when registered nurses are going on strike to protest staffing shortages, thousands of applicants who want to enter or advance in the profession are being turned away from nursing schools. Nearly 78,200 qualified applications were not offered spots at nursing schools last year, according to the American Association of Colleges of Nursing, which represents schools with baccalaureate and advanced degree programs. Staffing shortages are the main reason why nursing schools are not able to accept more students who want to become registered nurses. Staffing shortages are also a major factor in the current strike by more than 75,000 unionized employees, including registered nurses, at Kaiser Permanente. The national median salary for nursing school professors with master’s degrees is just under $89,000, according to the nursing college association.

Persons: preceptors, Preceptors, ”, Judith Jarosinski, Rick Garcia, David Auerbach, Cynthia McCurren, McCurren, Jarosinski, ” McCurren, Marie Ann Marino, Thomas, “, Marino, ” Marino Organizations: CNN, American Association of Colleges of Nursing, Salisbury University’s School of Nursing, Community, Organization, Nursing, Brandeis University, Kaiser Permanente, Bureau of Labor Statistics, School of Nursing, University of Michigan, Nurse.com, Thomas Jefferson University College of Nursing, Thomas Jefferson University, US Department of Health, Human Services, Loan, Salisbury School of Nursing, Faculty Academy, Maryland Higher Education Commission, Jefferson College of Nursing, Jefferson Health, Jefferson Locations: Salisbury, Maryland, Kaiser, Flint, Philadelphia

TOKYO (AP) — Japan's health ministry has approved Leqembi, a drug for Alzheimer’s disease that was jointly developed by Japanese and U.S. pharmaceutical companies. It's the first drug for treatment of the disease in a country with a rapidly aging population. Developed by Japanese drugmaker Eisai Co. and U.S. biotechnology firm Biogen Inc., the drug's approval in Japan comes two months after it was endorsed by the U.S. Food and Drug Administration. Eisai said it will conduct a post-marketing special use survey in all patients administered the drug until enough data is collected from unspecified number of patients under Japanese health ministry procedures. Eisai is committed to delivering Leqembi to people who need it and their families “as a new treatment,” said Haruo Naito, the company’s CEO.

Persons: Fumio Kishida, Kishida, Eisai, Leqembi, ”, Haruo Naito Organizations: TOKYO, Biogen Inc, U.S . Food, Drug Administration, Kyodo Locations: Japan

A few compounds picked by AI are now in development, but those bets will take years to play out. Reuters interviews with more than a dozen pharmaceutical company executives, drug regulators, public health experts and AI firms show, however, that the technology is playing a sizeable and growing role in human drug trials. The U.S. Food and Drug Administration (FDA) said it had received about 300 applications that incorporate AI or machine learning in drug development from 2016 through 2022. Without AI, Bayer said it would have spent millions more, and taken up to nine months longer to recruit volunteers. Finding real-world patients by mining electronic patient data can be done manually, but using AI speeds up the process dramatically.

Persons: Dado Ruvic, Jeffrey Morgan, Amgen, Badhri Srinivasan, Sameer Pujari, drugmaker Bayer, Bayer, Blythe Adamson, Roche, Richard Pazdur, Gen Li, John Concato, Natalie Grover, Martin Coulter, Julie Steenhuysen, Josephine Mason, David Clarke Organizations: Pharmaceutical Research, REUTERS, Pharmaceutical, Bayer, Novartis, Deloitte, U.S . Food, Drug Administration, Reuters, World Health, Flatiron Health, FDA, European Medicines Agency, FDA's Oncology, Excellence, Medical, FDA's Center, Drug, Research, Thomson Locations: U.S, Johannesburg, Texas, Finland, United States, London, Chicago

Majority Leader Chuck Schumer said Monday that staff for the chamber’s Sergeant-at-Arms — the Senate's official clothes police — will no longer enforce a dress code on the Senate floor. “Senators are able to choose what they wear on the Senate floor. I will continue to wear a suit.”Schumer did not mention Fetterman in his statement about the dress code, which will only apply to senators, not staff. “I plan to wear a bikini tomorrow to the Senate floor,” Collins joked. “Now I can vote from the Senate floor on Mondays,” Hawley said, noting that he usually wears a suit and tie every other day.

Persons: Chuck Schumer, Pennsylvania Sen, John Fetterman, ” Schumer, Fetterman, Kansas Sen, Roger Marshall, it’s, Schumer, “, ” Marshall, Republican Sen, Susan Collins of, ” Collins, ”, “ They’re, Missouri Sen, Josh Hawley, ” Hawley, Connecticut Sen, Chris Murphy, he’s, Sergeant, ” Murphy, ” Fetterman, Kevin Freking Organizations: WASHINGTON, Senators, Kansas, Republican, Senate, Democrat, Arms, Associated Press Locations: Pennsylvania, Kansas, Susan Collins of Maine, Missouri, Connecticut

Senate Majority Leader Charles Schumer, D-N.Y., conducts a news conference after the senate luncheons in the U.S. Capitol on Wednesday, June 21, 2023. Senate Majority Leader Chuck Schumer, D-N.Y., has quietly made changes to the Senate's informal dress code to allow senators to wear whatever they want on the floor, one person with direct knowledge told NBC News. The change would let Sen. John Fetterman, D-Pa., who is often seen wearing a hoodie and baseball shorts, wear his casual attire on the Senate floor whenever he wants. Fetterman, who was elected during last year's midterm elections, was seen wearing a suit and tie during his swearing-in in January. However, the senator has worn his casual clothes after he returned to the Senate following treatment for clinical depression earlier this year.

Persons: Charles Schumer, Chuck Schumer, Sen, John Fetterman, Fetterman Organizations: U.S, Capitol, NBC News

☆ Meta's VR technology is helping to train surgeons and treat patients, though costs remain a hurdle
▼ + stars: | 2023-09-09 | by ( Ashley Capoot | ) www.cnbc.com time to read: +14 min

David Paul Morris | Bloomberg | Getty ImagesJust days before assisting in his first major shoulder-replacement surgery last year, Dr. Jake Shine strapped on a virtual reality headset and got to work. Kettering Health Dayton is one of dozens of health systems in the U.S. working with emerging technologies like VR as one tool for helping doctors to train on and treat patients. Since the beginning of last year, Meta's Reality Labs unit, which develops the company's VR and AR, has lost over $21 billion. Meta Quest 3 VR headset. "The first virtual reality headset that I used was this big clunky headset that had all these wires it had to be connected to a laptop to function."

Persons: Mark Zuckerberg, David Paul Morris, Jake Shine, Shine, Zuckerberg, didn't, Jan Herzhoff, Brennan Spiegel, Spiegel, Caitlin Rawlins, Rawlins, there's, Brent Bamberger, Reem, she's, it's, Daboul, PrecisionOS, Danny Goel, Richard Miller, he's, Miller, They're, It's, Goel, Kettering's Bamberger, Rafael Grossmann, Grossmann, Glass, Hollie Adams Organizations: Bloomberg, Getty, Kettering Health Dayton, CNBC, Meta, VR, Facebook, Labs, Apple, Elsevier Health's, U.S . Department of Veterans Affairs, Spiegel, Software, Doctors, PrecisionOS, University of Rochester, Portsmouth Regional Hospital, Google, of Fine Locations: San Jose , California, U.S, Ohio, Sinai, Los Angeles, Cedars, New Hampshire, Mayfair , London

☆ Insight: What happens when a $2 million gene therapy is not enough
▼ + stars: | 2023-08-12 | by ( Deena Beasley | ) www.reuters.com time to read: +13 min

Their experience raises broader questions around other high-cost gene therapies coming to market, sometimes after accelerated regulatory approvals, drug pricing experts said. Gene therapies work by replacing genes – the body's blueprint for its development. The gene Zolgensma delivers instructs the body to make a protein vital for muscle control. If gene therapies do fall short, it becomes harder to justify prices that researchers have argued are already poor value. More recently, the first hemophilia gene therapy approved by the U.S. Food and Drug Administration was priced by CSL Behring at $3.5 million; 26 more gene therapies are in late-stage development, according to IQVIA.

Persons: Elizabeth Kutschke, Ben, Zolgensma, Ben Kutschke, neurologists, Sitra Tauscher, Wisniewski, Ben's, Roger Hajjar, Brigham Gene, Kutschke, Vasant Narasimhan, Stacie Dusetzina, Roche's, Biogen, Roche, Maha Radhakrishnan, Steven Pearson, It's, Sree Chaguturu, Amanda Cook, Weston, Jackson, Cook, Elizabeth, Jerry Mendell, Russell Butterfield, –, Biogen's, Mendell, UMR, Spinraza, Eric Cox, Caroline Humer, Sara Ledwith Organizations: Reuters, U.S, Novartis, IQVIA Institute, Human Data, Novartis Gene Therapies, Mass, Cell Therapy, U.S . Food, Drug Administration, CSL Behring, CSL, Nashville's Vanderbilt University School of Medicine, Clinical, Economic, CVS Health, Aetna, SMA, Nationwide Children's Hospital, University of Utah Health, Children's, UnitedHealth, Thomson Locations: Oak Park, Berwyn , Illinois, Swiss, U.S, Lebanon , Virginia, United States, Columbus , Ohio, Russia, Kazakhstan, Chicago

☆ Chief of Texas' largest county takes medical leave for depression
▼ + stars: | 2023-08-07 | by ( ) www.reuters.com time to read: +1 min

Harris County Judge Lina Hidalgo addresses the news media, the day after a deadly crush of fans during a performance by rapper Travis Scott at the Astroworld Festival, in Houston, Texas, U.S. November 6, 2021. REUTERS/Daniel Kramer/File PhotoHOUSTON, Aug 7 (Reuters) - Lina Hidalgo, chief executive of the third-largest U.S. county and the largest one in Texas, has checked in to a medical facility outside the state to be treated for clinical depression, she said on Monday. Hidalgo, a Democrat elected in 2018 to lead the county of 4.9 million residents, has battled Republican state officials over election administration and police funding. Last November, she won re-election as Harris County judge against a well-funded political novice with a slim margin of about 17,000 votes. Reporting by Gary McWilliams in Houston Editing by Matthew LewisOur Standards: The Thomson Reuters Trust Principles.

Persons: Lina Hidalgo, Travis Scott, Daniel Kramer, Harris, Hidalgo, Kim Ogg, Gary McWilliams, Matthew Lewis Organizations: REUTERS, Democrat, Republican, Thomson Locations: Harris, Houston , Texas, U.S, Texas, Hidalgo, county's, Houston

☆ Dassault Systemes' flagship platform sales slow, but targets confirmed
▼ + stars: | 2023-07-25 | by ( Victor Goury-Laffont | ) www.reuters.com time to read: +2 min

It confirmed its full-year and mid-term targets, saying it saw a renewed focus on investment in innovation from customers and pointing to a rebound in China. The group's shares slid as much as 6.7% however, putting them on track for their biggest one-day drop since April. JPMorgan said in a note that the overall picture looked "incrementally challenging" after important performance indicators, including for its flagship software platform 3DEXPERIENCE and clinical trial platform Medidata, slowed in the quarter. For the third quarter, Dassault Systemes expects revenue to reach between 1.4 billion and 1.42 billion euros, diluted earnings to come in between 0.26 and 0.27 euros per share, and an operating margin of between 30.2 and 30.5%. ($1 = 0.9034 euros)Reporting by Victor Goury-Laffont; Editing by Kirsti Knolle and Jan HarveyOur Standards: The Thomson Reuters Trust Principles.

Persons: Victor Goury, Kirsti Knolle, Jan Harvey Organizations: Dassault, JPMorgan, Dassault Systemes, Thomson Locations: China

☆ FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverage
▼ + stars: | 2023-07-06 | by ( Spencer Kimball | ) www.cnbc.com time to read: +8 min

Leqembi is the first Alzheimer's antibody treatment to receive full FDA approval. The antibody, administered twice monthly through intravenous infusion, targets a protein called amyloid that is associated with Alzheimer's disease. Medicare coverage is a crucial step to help older Americans with early Alzheimer's disease pay for the treatment. Costs may vary depending on whether the patient has supplemental Medicare coverage or other secondary insurance, according to the agency. Philipson and his colleagues at the University of Chicago estimated that delaying Medicare coverage of Alzheimer's antibody treatments by one year would result in $6.8 billion in increased spending.

Persons: Joanna Pike, Leqembi, Pike, David Knopman, Knopman, Anna Eshoo of, Nanette Barragan, There's, Tomas Philipson, Bush, Philipson, Sen, Bernie Sanders, Xavier Becerra, Sanders, Eisai Organizations: Drug Administration, Medicare, FDA, Alzheimer's Association, Mayo Clinic, Services, Health, University of Chicago, Senate Health, Human Services, Clinical Locations: U.S, Minnesota, Anna Eshoo of California

☆ Australia ushers in a new era of psychedelic medicine
▼ + stars: | 2023-06-30 | by ( Katie Hunt | ) edition.cnn.com time to read: +8 min

Australia may be the first country to regulate the therapeutic use of MDMA and psilocybin, but it isn’t alone in ushering in a new era of psychedelic medicine. In October 2022, Alberta became the first jurisdiction in Canada to regulate the use of psychedelic drugs. Combining psychotherapy with psychedelic drugs is thought to be necessary for a beneficial outcome. He said that psychedelic drugs resulted in “powerful altered states of consciousness that can be intensely therapeutic, but also intensely destabilizing. “If you have a regulated, insured, safe context, and a good psychotherapeutic relationship, and yes, there’s the potential for great benefit there.”However, Rucker stressed that psychedelic drugs were not “a chemical switch to make everything seem fine.

Persons: ”, haven’t, Colleen Loo, Loo, “, Cole Burston, Celia Morgan, Morgan, James Rucker, “ You’re, ” Morgan, ” Rucker, prescriber, Rucker Organizations: CNN, Goods Administration, US Food and Drug Administration, University of New, Black Dog Institute, The Royal, New Zealand College of Psychiatrists, Oregon Health Authority, Getty, University of Exeter, The New England, of Medicine, of Psychiatry, Neuroscience, King’s College London, Therapeutic Goods Locations: Australia, University of New South Wales, Sydney, RANZCP, Alberta, Canada, AFP, United Kingdom, The, psychopharmacology

☆ Lab crunch: British science has nowhere to go
▼ + stars: | 2023-06-20 | by ( Kate Holton | ) www.reuters.com time to read: +9 min

Property consultants Bidwells put demand for lab space in Cambridge at 1.19 million square feet (110,000 square metres) - but only 7,000 sq ft are available. That has led to an explosion in venture capital, with much of it coming from the United States. Michael Chen moved to Cambridge from the United States in 2012 to do a doctorate in chemistry. She leads a joint venture between Oxford University and Legal & General (LGEN.L) to build lab space and homes. Pioneer Group, which provides funding and lab space in Britain, said action was needed now to address the "crazy" demand.

Persons: Zoe, Toby Melville OXFORD, Ros Deegan, Catherine Elton, Bidwells, Elton, Deegan, Diarmuid O'Brien, Rishi Sunak's, Gordon Sanghera, Michael Chen, Artem Korolev, Anna Strongman, Strongman, Glenn Crocker, Alistair Cory, Qkine's Elton, Kate Holton, Toby Melville, David Clarke Organizations: University of Oxford, Science, REUTERS, European Union, Therapeutics, McKinsey, Oxford, Cambridge Enterprise, U.S, Oxford Nanopore Technologies, Reuters, Company, Cambridge, PACE, Laboratory, Oxford University, Legal, Thomson Locations: Kidlington, Oxford, Britain, England, Cambridge, United States, London, U.S, France, Boston, North America, Europe, Asia, China

☆ Bernie Sanders says price of Alzheimer's treatment is unconscionable, calls on HHS to take action
▼ + stars: | 2023-06-07 | by ( Spencer Kimball | ) www.cnbc.com time to read: +2 min

Sen. Bernie Sanders on Wednesday called on the U.S. Health and Human Services Department to take action to ensure seniors can actually afford the expensive Alzheimer's treatment Leqembi. Sanders, who chairs the Senate Health Committee, in a letter to HHS Secretary Xavier Becerra called the $26,500 annual price tag for Leqembi set by drugmakers Eisai and Biogen "unconscionable." Sanders said the "outrageously high price" of Leqembi "will prevent seniors who need this drug from receiving treatment." Most Medicare patients suffering from Alzheimer's would not be able to afford the 20% co-payment of more than $5,000 a year for Leqembi, Sanders said. Co-payments, along with coinsurance and deductibles, are medication and health services costs that patients must personally pay for out of pocket, as opposed to being covered by their health insurance.

Persons: Sen, Bernie Sanders, Sanders, Xavier Becerra, drugmakers Eisai, Becerra, Mr Organizations: U.S, Capitol, U.S . Health, Human Services Department, Health, Medicare, HHS, Services, Leqembi, Democratic, Senate, Clinical Locations: Washington , DC, Vermont

☆ Scientists propose long Covid definition based on key symptoms in large study
▼ + stars: | 2023-05-25 | by ( Spencer Kimball | ) www.cnbc.com time to read: +4 min

South_agency | E+ | Getty ImagesScientists funded by the federal government have proposed a definition of long Covid based on symptoms identified in a large study published Thursday in the Journal of the American Medical Association. The scientists assigned points based on how much each symptom distinguished participants with long Covid from those who did not catch the virus. There are no tests that can diagnose long Covid based on markers in the blood. Scientists participating in RECOVER are trying to understand the underlying biology that causes long Covid, which could potentially lead to such tests in the future. Horwitz said the proposed definition could help create a rubric to diagnose patients with long Covid in a manner similar to Lupus.

☆ F.D.A. Approves New Drug to Treat Hot Flashes
▼ + stars: | 2023-05-12 | by ( Christina Jewett | ) www.nytimes.com time to read: +3 min

“Hot flashes as a result of menopause can be a serious physical burden on women and impact their quality of life,” said Dr. Janet Maynard, an official with the F.D.A. Background: Symptoms have long been enduredHot flashes are the most common side effect of menopause for which women typically seek treatment, Astellas said. And the complaints of those who experience severe hot flashes and other symptoms of menopause are often dismissed in the workplace and elsewhere. Because signs of liver damage emerged in some patients during study of the drug, the F.D.A. What’s Next: The drug price may be prohibitiveAstellas said that the drug would cost $550 for a 30-day supply, not including rebates.

Search resuls for: "for Clinical"

25 mentions found